Recent Advances in Perioperative Immunotherapies in Lung Cancer
Biomolecules · 12.09.2023 · 13 (9) · 1377
DOI: 10.3390/biom13091377 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 12.09.2023. Verfasst von Shota Fukuda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama 589-8511, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Several clinical trials have been revolutionizing the perioperative treatment of early-stage non-small cell lung cancer (NSCLC). Many of these clinical trials involve cancer immunotherapies with antibody drugs that block the inhibitory immune checkpoints programmed death 1 (PD-1) and its ligand PD-L1. While these new treatments are expected to improve the treatment outcome of NSCLC patients after pulmonary resection, several major clinical questions remain, including the appropriate timing of immunotherapy (neoadjuvant, adjuvant, or both) and the identification of patients who should be treated with neoadjuvant and/or adjuvant immunotherapies, because some early-stage NSCLC patients are cured by surgical resection alone. In addition, immunotherapy may induce immune-related adverse events that will require permanent treatment in some patients. Based on this fact as well, it is desirable to select appropriate patients for neoadjuvant/adjuvant immunotherapies. So far, data from several important trials have been published, with findings demonstrating the efficacy of adjuvant atezolizumab (IMpower010 trial), neoadjuvant nivolumab plus platinum-doublet chemotherapy (CheckMate816 trial), and several perioperative (neoadjuvant plus adjuvant) immunotherapies (AEGEAN, KEYNOTE-671, NADIM II, and Neotorch trials). In addition to these key trials, numerous clinical trials have reported a wealth of data, although most of the above clinical questions have not been completely answered yet. Because there are so many ongoing clinical trials in this field, a comprehensive understanding of the results and/or contents of these trials is necessary to explore answers to the clinical questions above as well as to plan a new clinical trial. In this review, we comprehensively summarize the recent data obtained from clinical trials addressing such questions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama 589-8511, Japan.
ORCID-Profile: Akira Hamada, Yasuhiro Tsutani
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Fukuda, S., Suda, K., Hamada, A., & Tsutani, Y. (2023). Recent Advances in Perioperative Immunotherapies in Lung Cancer. Biomolecules, 13(9), 1377. https://doi.org/10.3390/biom13091377
Vancouver
Fukuda S, Suda K, Hamada A, Tsutani Y. Recent Advances in Perioperative Immunotherapies in Lung Cancer. Biomolecules. 2023;13(9):1377. doi:10.3390/biom13091377
BibTeX
@article{Fukuda2023,
author = {Fukuda, Shota and Suda, Kenichi and Hamada, Akira and Tsutani, Yasuhiro},
title = {Recent Advances in Perioperative Immunotherapies in Lung Cancer},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {9},
pages = {1377},
doi = {10.3390/biom13091377}
}
EUVIMED